Aptevo Therapeutics Inc.

Cash-strapped Alligator Biosciences is reducing its workforce and early-stage activities to put all its focus on preparing its pancreatic cancer candidate, mitazalimab, for Phase III trials. The Swedi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. JCR Signs Deal With Sumitomo On Izcargo

When one public company acquires another the conventional wisdom is that the stock prices of acquired and acquirer move in different directions. The most logical move is for the acquired company’s val

Alligator Bioscience AB 's partnering talks for mitazalimab are set to step up a gear after the Swedish firm posted promising mid-stage data on the drug as a potential treatment for pancreatic cancer.